pp 1–7 | Cite as

Association of NM23 polymorphisms and clinicopathological features and recurrence of invasive pituitary adenomas

  • Hua Wang
  • Wenyuan SangEmail author



Pituitary adenomas (PAs) are intracranial tumors, deriving from anterior pituitary cells. Previously, expression of non-metastasis-23 (NM23) gene has been shown to correlate with the progression of PAs. In this study, we aim to determine whether there is association between specific NM23 polymorphisms and invasive pituitary adenoma (IPA).


Genotypes of rs2302254 and rs16949649 of NM23 were identified in the peripheral venous blood of patients by PCR-RLFP. Next, the correlation between specific genotypes of rs2302254 and rs16949649 and risk of IPA was investigated. Finally, the correlations between NM23 polymorphisms and tumor size, Ki67 LI and recurrence of IPA were analyzed with 3 to 24 months follow-up for the enrolled patients.


We observed that the TT genotype at rs16949649 correlated closely with a high risk of IPA, while CC and CT genotypes reduced the risk of IPA. CC genotype at rs2302254 increased the risk of IPA, while CT and TT genotypes reduced the risk of IPA. Trs16949649Crs2302254 haplotype of NM23 was found to be a high-risk haplotype for IPA. TT genotype at rs16949649 and CC genotype at rs2302254 were associated with higher rates of tumors larger than 20 mm, Ki67 LI and tumor recurrence.


Taken together, the present study provides evidence that NM23 polymorphisms are closely associated with the incidence and recurrence of IPA. Specifically, TT genotype at rs16949649 and CC genotype at rs2302254 are risk factors of IPA. NM23 polymorphisms could therefore be used as a reference for clinical diagnosis and prognosis of IPA.


Invasive pituitary adenoma NM23 Polymorphisms Pathological characteristics Recurrence Haplotype analysis 



We would like to give our sincere appreciation to the reviewers for their helpful comments on this article.



Compliance with ethical standards

Conflicts of interest

The authors have declared that no conflicting interests exist.

Ethics approval

The study was conducted with the approval of the Ethics Committee of Chifeng Municipal Hospital. Written informed consents were signed by all participating patients.


  1. 1.
    Wu JL, Qiao JY, Duan QH (2016) Significance of TNF-alpha and IL-6 expression in invasive pituitary adenomas. Genet Mol Res. CrossRefPubMedGoogle Scholar
  2. 2.
    Lan X, Gao H, Wang F, Feng J, Bai J, Zhao P, Cao L, Gui S, Gong L, Zhang Y (2016) Whole-exome sequencing identifies variants in invasive pituitary adenomas. Oncol Lett 12(4):2319–2328CrossRefGoogle Scholar
  3. 3.
    Ji-Hu Y, Guo-Dong H, Tao J, Hai-Dong W, Yu-Fei L, Jian G, Zhen L, Wei-Ping L (2018) Endoscopic endonasal surgery treatment strategies for invasive pituitary adenoma: analysis of four approaches. World Neurosurg 115:5–13CrossRefGoogle Scholar
  4. 4.
    Liu C, Gao H, Cao L, Gui S, Liu Q, Li C, Li D, Gong L, Zhang Y (2016) The role of FSCN1 in migration and invasion of pituitary adenomas. Mol Cell Endocrinol 419:217–224CrossRefGoogle Scholar
  5. 5.
    Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15(1):71–83CrossRefGoogle Scholar
  6. 6.
    Gao H, Xue Y, Cao L, Liu Q, Liu C, Shan X, Wang H, Gu Y, Zhang Y (2017) ESR1 and its antagonist fulvestrant in pituitary adenomas. Mol Cell Endocrinol 443:32–41CrossRefGoogle Scholar
  7. 7.
    Zhong CH, Tao B, Wu Y, Peng LL, Zhou PZ, Chen LG, Jiang S (2015) The Role of cancer-associated fibroblasts in invasive behavior of pituitary adenoma. Sichuan Da Xue Xue Bao Yi Xue Ban 46(5):673–678PubMedGoogle Scholar
  8. 8.
    Boissan M, De Wever O, Lizarraga F, Wendum D, Poincloux R, Chignard N, Desbois-Mouthon C, Dufour S, Nawrocki-Raby B, Birembaut P, Bracke M, Chavrier P, Gespach C, Lacombe ML (2010) Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res 70(19):7710–7722CrossRefGoogle Scholar
  9. 9.
    Jarrett SG, Novak M, Dabernat S, Daniel JY, Mellon I, Zhang Q, Harris N, Ciesielski MJ, Fenstermaker RA, Kovacic D, Slominski A, Kaetzel DM (2012) Metastasis suppressor NM23-H1 promotes repair of UV-induced DNA damage and suppresses UV-induced melanomagenesis. Cancer Res 72(1):133–143CrossRefGoogle Scholar
  10. 10.
    Buxton IL, Yokdang N (2011) Extracellular NM23 signaling in breast cancer: incommodus verum. Cancers 3(3):2844–2857CrossRefGoogle Scholar
  11. 11.
    Boissan M, Lacombe ML (2012) NM23, an example of a metastasis suppressor gene. Bull Cancer 99(4):431–440CrossRefGoogle Scholar
  12. 12.
    Li Y, Kang S, Qin JJ, Wang N, Zhou RM, Sun HY (2012) nm23 gene polymorphisms are associated with survival of patients with epithelial ovarian cancer but not with susceptibility to disease. Gynecol Oncol 126(3):455–459CrossRefGoogle Scholar
  13. 13.
    Li AL, Zhou X, Wang ZN, Song YX, Gao P, Miao Y, Zhu JL, Xu HM (2012) Associations of non-metastatic cells 1 gene polymorphisms with lymph node metastasis risk of gastric cancer in Northern Chinese population. Tumour Biol 33(6):2159–2166CrossRefGoogle Scholar
  14. 14.
    Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96(2):195–208CrossRefGoogle Scholar
  15. 15.
    Negm HM, Al-Mahfoudh R, Pai M, Singh H, Cohen S, Dhandapani S, Anand VK, Schwartz TH (2017) Reoperative endoscopic endonasal surgery for residual or recurrent pituitary adenomas. J Neurosurg 127(2):397–408CrossRefGoogle Scholar
  16. 16.
    Qu S, Long J, Cai Q, Shu XO, Cai H, Gao YT, Zheng W (2008) Genetic polymorphisms of metastasis suppressor gene NME1 and breast cancer survival. Clin Cancer Res 14(15):4787–4793CrossRefGoogle Scholar
  17. 17.
    Huang XI, Zhao W, Li Y, Kang S (2015) Association between nm23 gene polymorphisms and the risk of endometriosis. Biomed Rep 3(6):874–878CrossRefGoogle Scholar
  18. 18.
    Takino H, Herman V, Weiss M, Melmed S (1995) Purine-binding factor (nm23) gene expression in pituitary tumors: marker of adenoma invasiveness. J Clin Endocrinol Metab 80(5):1733–1738PubMedGoogle Scholar
  19. 19.
    Feng CY, Wang PH, Tsai HT, Tee YT, Ko JL, Chen SC, Lin CY, Han CP, Yang JS, Liu YF, Lin LY, Yang SF (2010) Polymorphisms of human nonmetastatic clone 23 type 1 gene and neoplastic lesions of uterine cervix. Reprod Sci 17(10):886–893CrossRefGoogle Scholar
  20. 20.
    Fang M, Tao Y, Liu Z, Huang H, Lao M, Huang L, Zhu B (2017) Meta-analysis of the relationship between NM23 expression to gastric cancer risk and clinical features. Biomed Res Int 2017:8047183PubMedPubMedCentralGoogle Scholar
  21. 21.
    Wu HW, Gao LD, Wei GH (2013) hMSH2 and nm23 expression in sporadic colorectal cancer and its clinical significance. Asian Pac J Cancer Prev 14(3):1995–1998CrossRefGoogle Scholar
  22. 22.
    Altas M, Bayrak OF, Ayan E, Bolukbasi F, Silav G, Coskun KK, Culha M, Sahin F, Sevli S, Elmaci I (2010) The effect of polymorphisms in the promoter region of the MMP-1 gene on the occurrence and invasiveness of hypophyseal adenoma. Acta Neurochir 152(9):1611–1617 (Discussion 1617) CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.1st Ward of Department of NeurosurgeryChifeng Municipal HospitalChifengPeople’s Republic of China

Personalised recommendations